Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Sharps Technology Inc. Warrant (STSSW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: STSSW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -53.12% | Avg. Invested days 7 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.92 | 52 Weeks Range 0.01 - 0.14 | Updated Date 05/24/2025 |
52 Weeks Range 0.01 - 0.14 | Updated Date 05/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.96 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -42.67% | Return on Equity (TTM) -75.14% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 1017855 |
Shares Outstanding - | Shares Floating 1017855 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Sharps Technology Inc. Warrant
Company Overview
History and Background
Sharps Technology, Inc. is a medical device company focused on developing and commercializing innovative drug delivery systems, including its prefilled syringe technology. The warrant gives the holder the right to purchase shares of Sharps Technology common stock under certain conditions.
Core Business Areas
- Prefilled Syringe Technology: Sharps Technology focuses on developing and commercializing prefilled syringes that aim to improve safety and efficiency in drug delivery.
Leadership and Structure
Details about the specific leadership team and organizational structure for Sharps Technology can typically be found on their investor relations website or in SEC filings.
Top Products and Market Share
Key Offerings
- Prefilled Syringes: Sharps Technology's main product is its prefilled syringe technology. Information on exact market share is often proprietary, but prefilled syringes overall are a growing market driven by demand for safer and more convenient drug delivery. Competitors include Becton Dickinson (BDX), Gerresheimer, and Schott.
Market Dynamics
Industry Overview
The medical device industry is characterized by innovation, regulatory scrutiny, and competition. The prefilled syringe market is growing due to the increasing demand for single-use and ready-to-use injectable medications.
Positioning
Sharps Technology aims to capture a share of the prefilled syringe market with its proprietary technology and focus on safety and ease of use.
Total Addressable Market (TAM)
The prefilled syringe market is estimated to be in the billions of dollars globally. Sharps Technology's positioning depends on its ability to gain regulatory approvals, secure partnerships, and effectively market its products.
Upturn SWOT Analysis
Strengths
- Proprietary prefilled syringe technology
- Focus on safety and ease of use
- Potential partnerships with pharmaceutical companies
Weaknesses
- Limited commercialization experience
- Reliance on regulatory approvals
- Competition from established players
Opportunities
- Growing demand for prefilled syringes
- Expansion into new therapeutic areas
- Strategic alliances and acquisitions
Threats
- Regulatory hurdles
- Technological advancements by competitors
- Price pressures in the medical device market
Competitors and Market Share
Key Competitors
- BDX
- GGMGF
- SCHN.DE
Competitive Landscape
Sharps Technology competes with larger, established players in the medical device industry. Its success depends on its ability to differentiate its technology and secure market share.
Growth Trajectory and Initiatives
Historical Growth: Refer to Sharps Technology's (STSS) SEC filings for details.
Future Projections: Analyst projections for Sharps Technology's (STSS) future growth can be found on financial websites.
Recent Initiatives: Recent initiatives are typically detailed in company press releases and investor presentations.
Summary
Sharps Technology Inc. is focused on a growing market, has proprietary technology, and is working towards commercialization. Regulatory hurdles and intense competition from established players in the medical device market pose key risks. Financial performance is closely tied to Sharps Technology (STSS) and its future ability to scale and penetrate the prefilled syringe market. The warrant is a derivative security, therefore its performance will depend on that of the common stock.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Industry reports
- Financial news sources
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investing in warrants involves risks, including the risk of losing your entire investment.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sharps Technology Inc. Warrant
Exchange NASDAQ | Headquaters Melville, NY, United States | ||
IPO Launch date 2022-04-14 | CEO & Director Mr. Robert M. Hayes | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 55 | Website https://sharpstechnology.com |
Full time employees 55 | Website https://sharpstechnology.com | ||
Sharps Technology, Inc., a medical device and pharmaceutical packaging company, engages in the design, research and development, manufacturing, and commercialization of safety syringe products in the United States. The company provides safety syringe products comprising Securgard, Sologard, and Sharps Provensa that are ultra-low waste syringes for passive, and safety and reuse prevention features, as well as develops prefillable syringe systems. The company was incorporated in 2017 and is based in Melville, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.